ArticleAmerican journal of obstetrics and gynecology2011
Size of the nanovectors determines the transplacental passage in pregnancy: study in rats.
Article in American journal of obstetrics and gynecology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Defining the landscape of prenatal nanomedicine and a roadmap for future research.Nanomedicine (London, England) · 2025Article
- The Application of Engineered Nanomaterials in Perinatal Therapeutics.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Delivery of PAMAM dendrimers and dendriplexes across natural barriers (blood-brain barrier and placental barrier) in healthy pregnant mice.Discover nano · 2024Article
- Folate-mediated Transport of Nanoparticles across the Placenta.Pharmaceutical nanotechnology · 2024Article
- Advance in placenta drug delivery: concern for placenta-originated disease therapy.Drug delivery · 2023Review
- Targeted drug delivery for maternal and perinatal health: Challenges and opportunities.Advanced drug delivery reviews · 2021Review
- Fetotoxicity of Nanoparticles: Causes and Mechanisms.Nanomaterials (Basel, Switzerland) · 2021Review
- Nanoparticles in pregnancy: the next frontier in reproductive therapeutics.Human reproduction update · 2021Review
- Developmental Neurotoxicity Screening for Nanoparticles Using Neuron-Like Cells of Human Umbilical Cord Mesenchymal Stem Cells: Example with Magnetite Nanoparticles.Nanomaterials (Basel, Switzerland) · 2020Article
- Promising opportunities and potential risk of nanoparticle on the society.IET nanobiotechnology · 2020Review
- Article
- Nanoparticles and female reproductive system: how do nanoparticles affect oogenesis and embryonic development.Oncotarget · 2017Review
- Maternal-placental-fetal biodistribution of multimodal polymeric nanoparticles in a pregnant rat model in mid and late gestation.Scientific reports · 2017Article
- Toxicity of Nanoparticles on the Reproductive System in Animal Models: A Review.Frontiers in pharmacology · 2017Review
- Nanotoxicity overview: nano-threat to susceptible populations.International journal of molecular sciences · 2014Review
- Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model.International journal of pharmaceutics · 2013Article
- Effects of nanotoxicity on female reproductivity and fetal development in animal models.International journal of molecular sciences · 2013Review
- Biocompatibility assessment of Si-based nano- and micro-particles.Advanced drug delivery reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThe objective of the study was to examine whether the size of silicon nanovectors (SNVs) inhibits their entrance into the fetal circulation. STUDY
designPregnant rats were intravenously administered with SNVs or saline. The SNVs were spherical particles with 3 escalating diameters: 519 nm, 834 nm, and 1000 nm. The maternal and fetal distribution of SNVs was assessed.
resultsIn animals that received 1000 or 834 nm SNV, silicon (Si) levels were significantly higher in the maternal organs vs the saline group, whereas the silicon levels in fetal tissues were similar to controls. However, in animals receiving 519 nm SNVs, fetal silicon levels were significantly higher in the SNV group compared with the saline group (5.93 ± 0.67 μg Si per organ vs 4.80 ± 0.33, P = .01).
conclusionLarger SNVs do not cross the placenta to the fetus and, remaining within the maternal circulation, can serve as carriers for harmful medications in order to prevent fetal exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.